Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

World Cancer Day – February 2022

World Cancer Day is celebrated around the world in February in February and innovative Trials wants to take this opportunity to raise awareness around cancer

Innovative Trials

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

No green light from NICE for innovative cancer treatments

The Institute of Cancer Research is asking for more flexibility and consideration to make it easier for cancer patients to access new treatments on the NHS

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

- PMLiVE

New drug available on NHS will benefit lung cancer patients

Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1,000 patients in year...

- PMLiVE

FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

The review of Evrysdi has been developed for pre-symptomatic babies under two months old with spinal muscular atrophy

- PMLiVE

Personalised medicine: driving a need for greater diversity in clinical trials

Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today.

Innovative Trials

- PMLiVE

Cervical Cancer Prevention Month

In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer

Innovative Trials

- PMLiVE

AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients

The phase 3 trial results for patients diagnosed with first-line unresectable liver cancer showed a 31% survival rate after three years

- PMLiVE

Meet Innovative Trials at SCOPE 2022

Stop by Booth 1015 to meet the Innovative Trials' team during SCOPE 2022

Innovative Trials

- PMLiVE

AstraZeneca’s Enhertu receives FDA grant for priority review

The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression

The New Normal: Upcoming Trends in Clinical Trials

Samuel Searcy, Founder & CEO of CliniStart, shares his expert insights into trends, current gaps, and future predictions for clinical trials. Among many other things, we also dive into his...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links